reference/14671352

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14671352

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	2558
issn	1557-3265 1078-0432
issueIdentifier	7
pageRange	2552-2558
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	2552
bibliographicCitation	Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009 Apr 01;15(7):2552–8. doi: 10.1158/1078-0432.ccr-08-1978. PMID: 19318484.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8128fbf126bb360d30fbad3fb9bac16e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8e38ff904933508e245366964dc33052 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37ad1e669fd0d49514c2ef09eddc64be http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a258b4c0f450cf0f3cbc2e3b9d2e586 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_59d875af7630ce56e5038e4e945ccc69 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac3e8a08478364a8a337937703a81afc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0f4025e2f32589cd78433b77245456f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f7f81f06a6aef2a21e58c404517026a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60d87e37f11315cccab7a96272ff330e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c873640518537509bb52c133f1a8f435 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa95dc87a9fc1b824427414d0d95b9a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32b67089a7d60af04d65313c2971cad5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1beaf5d7e7f2515feca03c9920e47525 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b4e8edc0bbe2061c64c9b296e23c919 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7ac952db92449047efcc96abca61bb44 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16e50495893cadf39e63939d803aeb4f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28efc5d3dd0c76165c377d7080812c83 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3d310dc242b23475474ba3be9c840e06
date	2009-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1158/1078-0432.ccr-08-1978 https://pubmed.ncbi.nlm.nih.gov/19318484
isPartOf	https://portal.issn.org/resource/ISSN/1557-3265 https://portal.issn.org/resource/ISSN/1078-0432 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
discusses	http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0593322 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0543872 http://id.nlm.nih.gov/mesh/M0018350
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009369Q000188 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D047428Q000009 http://id.nlm.nih.gov/mesh/D011804Q000009
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011804Q000627 http://id.nlm.nih.gov/mesh/D009369Q000175 http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D018719Q000037 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D000970Q000493 http://id.nlm.nih.gov/mesh/D047428Q000493 http://id.nlm.nih.gov/mesh/D011804Q000493 http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D066246Q000037 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_626dfbbe49a6d994e766d55aeeff23e8 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9915743 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245740308

Total number of triples: 80.